Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
1.
Arch Ital Urol Androl ; 70(5): 247-9, 1998 Dec.
Article in Italian | MEDLINE | ID: mdl-9882907

ABSTRACT

We examine some surgical techniques proposed for phallic reconstruction. Together with cutaneous flaps, muscle-cutaneous flaps, who present the advantage of more constant results, are progressively listed. We also present a personal technique of phallic reconstruction with double prosthesis: one external, vascular and one internal, for the erection.


Subject(s)
Penis/surgery , Humans , Male , Muscle, Skeletal/transplantation , Penile Implantation , Penile Neoplasms/surgery , Penile Prosthesis , Penis/injuries , Prosthesis Design , Skin Transplantation/methods , Surgical Flaps , Transplantation, Heterotopic , Transsexualism/surgery
2.
Arch Ital Urol Androl ; 67(5): 299-302, 1995 Dec.
Article in Italian | MEDLINE | ID: mdl-8589743

ABSTRACT

In this work the Authors speak about topical treatment in diagnosis and therapy of erectile deficit with prostaglandin, papaverine, phentolamine, V.I.P., nitroglycerine, minoxidil and others. These drugs must have some chemicophysical trait to be adsorbed by the skin. The concepts of microangiotettonic, microangiopathy, microangiokinesis are very important in erectile dysfunctions. For the future there are perspectives to use microvasculokinesic and antiperossidasic complex, alone or in association with intravenous pharmacotherapy.


Subject(s)
Erectile Dysfunction/drug therapy , Administration, Cutaneous , Humans , Male , Minoxidil/administration & dosage , Papaverine/administration & dosage , Phentolamine/administration & dosage , Vasoactive Intestinal Peptide/administration & dosage , Vasodilator Agents/administration & dosage , Yohimbine/administration & dosage
3.
Minerva Urol Nefrol ; 45(3): 113-5, 1993 Sep.
Article in Italian | MEDLINE | ID: mdl-8278877

ABSTRACT

The authors present the long-term of adjuvant chemotherapy using M-VEC scheme (Mtx 20 mg/mq; vinblastine 0.1 mg/kg; CDDP 40 mg/mq; epirubicin 30 mg/mq each 21 day for six cycles) effected in 28 patients (21 males and 7 women with average age of 67) undergone radical cystectomy for invasive bladder carcinoma p G2-3 T-4 N + M0. Total survival after 5 years was 28.6% while disease-free survival is 18.8%; in 71.3% there are been clinical progression and the mortality to 5 years was 62%.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Urinary Bladder Neoplasms/drug therapy , Aged , Chemotherapy, Adjuvant , Cisplatin/administration & dosage , Epirubicin/administration & dosage , Female , Follow-Up Studies , Humans , Male , Methotrexate/administration & dosage , Middle Aged , Neoplasm Invasiveness , Survival Rate , Urinary Bladder Neoplasms/mortality , Urinary Bladder Neoplasms/pathology , Urinary Bladder Neoplasms/surgery , Vinblastine/administration & dosage
4.
Arch Ital Urol Androl ; 65(2): 167-71, 1993 Apr.
Article in Italian | MEDLINE | ID: mdl-8330062

ABSTRACT

Authors show results of adjuvant chemoimmunotherapeutic approach (0, 10 mg/kg Vinblastine every three weeks plus INF - alpha 2a - and INF - alpha 2b in a dose of 3 x 10(6) U.I. three times a week) adopted after radical nephrectomy in 45 patients with renal carcinoma (p. T3/4. NO.MO; pT3/4. N+/O. M+/O). The treatment may be summed up: 1# to effect a regression of metastasis that is not possible surgically to remove either because of its location or extent; 2) to limit micrometastatic diffusion in patients with N+. 3) It is important to perform this treatment in stage T3 N0M0 where clinical progression is (21.1%) in our group.


Subject(s)
Carcinoma/therapy , Immunologic Factors/therapeutic use , Interferon-alpha/therapeutic use , Kidney Neoplasms/therapy , Vinblastine/therapeutic use , Carcinoma/mortality , Carcinoma/pathology , Chemotherapy, Adjuvant , Combined Modality Therapy , Humans , Interferon alpha-2 , Kidney Neoplasms/mortality , Kidney Neoplasms/pathology , Neoplasm Metastasis , Neoplasm Staging , Neoplasms, Multiple Primary , Nephrectomy , Recombinant Proteins , Survival Rate , Treatment Outcome
6.
Minerva Urol Nefrol ; 44(3): 191-3, 1992.
Article in Italian | MEDLINE | ID: mdl-1492270

ABSTRACT

The Authors report their experience of topical and intracavernous treatment with papaverine and phentolamine in patients with erectile dysfunction from May 1988 to March 1992. Topical application of drug cream proves efficacious both alone or combined with intracavernous injection with PGE1. Topical treatment besides may be carried out without systemic or local complications.


Subject(s)
Erectile Dysfunction/drug therapy , Papaverine/administration & dosage , Phentolamine/administration & dosage , Administration, Cutaneous , Adolescent , Adult , Aged , Alprostadil/administration & dosage , Alprostadil/therapeutic use , Drug Combinations , Drug Therapy, Combination , Erectile Dysfunction/diagnosis , Gels , Humans , Injections , Male , Middle Aged , Papaverine/therapeutic use , Penis , Phentolamine/therapeutic use
7.
Minerva Urol Nefrol ; 44(3): 209-12, 1992.
Article in Italian | MEDLINE | ID: mdl-1492273

ABSTRACT

Transitional cell carcinoma of the urethra in men after radical cystectomy for bladder carcinoma have an incidence which varies from 4 to 18%. The Authors present their experience of 6 cases (6/196; 3.06%) analysing the characteristics of the urethral neoplasm and confirming the systematic cystourethrectomy when there is a urethra prostatic and bladder neck infiltration or when there is a urethral ca in situ. It also underlines the role of the clinical, radiological, cytological and urethro-endoscopical follow-up in patients who have undergone a cystoprostatovesciculectomy.


Subject(s)
Carcinoma, Transitional Cell/secondary , Cystectomy , Neoplasm Recurrence, Local/surgery , Urethral Neoplasms/secondary , Urinary Bladder Neoplasms/surgery , Aged , Aged, 80 and over , Amputation, Surgical , Carcinoma in Situ/secondary , Carcinoma in Situ/surgery , Carcinoma, Transitional Cell/epidemiology , Carcinoma, Transitional Cell/surgery , Humans , Incidence , Male , Neoplasm Invasiveness , Penile Neoplasms/secondary , Penile Neoplasms/surgery , Postoperative Period , Prostatectomy , Seminal Vesicles/surgery , Urethra/surgery , Urethral Neoplasms/epidemiology , Urethral Neoplasms/surgery , Urinary Diversion
8.
Arch Ital Urol Nefrol Androl ; 62(1): 101-5, 1990 Mar.
Article in Italian | MEDLINE | ID: mdl-2141701

ABSTRACT

The choice of the tissue to build up the neovagina is an important step in the surgical treatment of transsexualism. Both the penile skin and an intestinal segment are possible solutions to the problem. However intestinal segments have some defects like continuous secretions and painful intercourse. For these reasons the authors prefer the penile skin with the neuro-vascular bundle preserved. One hundred cases of this surgery are presented.


Subject(s)
Penis/surgery , Surgery, Plastic/methods , Transsexualism/surgery , Vagina/surgery , Female , Humans , Male
9.
Arch Ital Urol Nefrol Androl ; 62(1): 113-6, 1990 Mar.
Article in Italian | MEDLINE | ID: mdl-2141703

ABSTRACT

The surgery for both male and female transsexuals causes great difference in the behavior of operated patients. Then it is very important to analyze the variations of three parameters before and after operation: 1) the presence and the character of sexual feeling and the modality of sexual intercourse; 2) possibility of orgasm; 3) working behavior. The authors present the results of their study on 16 male transsexuals and 4 female transsexuals.


Subject(s)
Sex , Transsexualism/surgery , Work , Adult , Female , Follow-Up Studies , Humans , Male , Middle Aged , Transsexualism/psychology
10.
Minerva Urol Nefrol ; 41(3): 195-7, 1989.
Article in Italian | MEDLINE | ID: mdl-2617375

ABSTRACT

The therapeutic efficacy of chemotherapy in bladder's carcinoma is today supported by many statistical reports; the response rates are ranging from 35% to 45%. Results of the treatment with adjuvant chemotherapy (M-VEC in 22 patients with or without metastatic tumor are presented. Favourable objective responses were seen in 25% of the patients. The conclusion is drawn that this therapy is very useful in the treatment of metastatic diseases, but it can be used also in non-metastatic (M0) patients to prevent the growth of micrometastasis.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma/drug therapy , Urinary Bladder Neoplasms/drug therapy , Aged , Carcinoma/surgery , Cisplatin/administration & dosage , Combined Modality Therapy , Cystectomy , Drug Evaluation , Epirubicin/administration & dosage , Humans , Methotrexate/administration & dosage , Middle Aged , Urinary Bladder Neoplasms/surgery , Vinblastine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...